Updated Oct. 1, 2012 at 7:53 a.m.

Premium Lock Study: GSK drug as effective as Pfizer's for kidney cancer

Published: 2012-10-01 06:38:00
Updated: 2012-10-01 07:53:28

Cancer research Cancer research Image 1 of 2 · Next Image…

For both drugs, the average progression-free survival was slightly more than 10 months, according to a GSK-funded study of 1,100 patients that was announced Monday....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 Bloomberg. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll